New Chemotherapy Targets Sick Tumors Remotely
- PESSAC, france – A team of researchers in Pessac, near Bordeaux, is developing a novel approach to chemotherapy that could revolutionize cancer treatment.Doxanano, a local biotech startup, is...
- The current standard of care in chemotherapy benefits approximately 60% of cancer patients, but often at a meaningful cost to their quality of life.
- “The treatment of each patient is diffused according to his ability to support anti-cancer molecules.”
Remote-Controlled Chemotherapy Shows Promise in Cancer Treatment
Table of Contents
- Remote-Controlled Chemotherapy Shows Promise in Cancer Treatment
- Remote-Controlled Chemotherapy: A Promising New Approach to Cancer Treatment
- What is the current standard of care for chemotherapy?
- What are the limitations of traditional chemotherapy?
- How does remote-controlled chemotherapy work?
- Who is behind this new technology?
- What are the potential benefits of this new treatment?
- What types of cancer might this treatment be used for?
- When will human trials begin?
- Where is Doxanano located?
- What support has Doxanano received?
- How is Doxanano funding its research?
- Summary of Remote-Controlled Chemotherapy vs. Traditional Chemotherapy
PESSAC, france – A team of researchers in Pessac, near Bordeaux, is developing a novel approach to chemotherapy that could revolutionize cancer treatment.Doxanano, a local biotech startup, is pioneering a method to remotely control chemotherapy, perhaps minimizing side effects adn maximizing effectiveness.
The current standard of care in chemotherapy benefits approximately 60% of cancer patients, but often at a meaningful cost to their quality of life. The new approach aims to refine this treatment, making it more precise and less harmful.
“The treatment of each patient is diffused according to his ability to support anti-cancer molecules.”
Isabel Marey-Semper, a neuropharmacology doctor and co-founder of doxanano, explained the limitations of traditional chemotherapy. “the paradox of chemotherapy is a dose locally present in the tumor too weak to be completely effective and a dose too strong in the healthy organs to be harmless,” she said. “Currently, the treatment is adjusted based on the patient’s tolerance, not the optimal dose for eradicating the tumor.”
Marey-Semper added, “We want to reverse this paradigm by delivering unprecedented doses directly to the tumor while safeguarding healthy organs.”
Innovative Nanocarriers Target Tumors
The innovation hinges on specially designed nanocarriers developed by physiochemist Sébastien Lecommandoux, another co-founder of Doxanano and chair of the “technological innovation Liliane Bettencourt” at the Collège de France. These synthetic nanocarriers, called DXN, are stable under physiological conditions but degrade when exposed to radiotherapy.
Lecommandoux described the process: “The nanocarriers are essentially safes made of macromolecules that remain stable until activated by X-ray radiation. this allows for targeted drug release with remarkable precision.”
Radiotherapy as a Trigger
Dr. Charles Dupin, a cancerologist and radiotherapist at the Bordeaux University hospital, collaborated with Doxanano to integrate radiotherapy into the treatment.Dupin,an expert in ENT,gastrointestinal,and stereotaxic radiotherapy,highlighted the potential of this combined approach. ”We have been seeking therapeutic solutions that can be triggered by radiation for a long time,” he said. “Remote-controlled chemotherapy offers incredible possibilities, potentially applicable to all solid tumors.”
The goal is to improve patient survival rates and enhance their quality of life. The initial request of this therapy is focused on advanced rectal tumors, in collaboration with doctors-researchers Charles Dupin and Samuel Amintas, as well as professors Véronique Sellly and Sandrine Dabernat, of the CHU de Bordeaux.
Doxanano anticipates beginning its frist human trials by the end of 2028,pending the completion of preclinical and clinical testing,and regulatory approvals.
Pessac to Host Production
“Our initial animal studies have been very promising,” Marey-Semper said. “The fluorescent nanocarriers effectively target tumors and demonstrate excellent safety profiles, being well-tolerated by the body.” While Doxanano’s headquarters are in Paris, its research activities and future manufacturing plant are planned for Pessac.
The biotech startup, co-founded by Isabel Marey-Semper, Sébastien Lecommandoux, and Leslie Dubrana, a chemical engineer and nanomedicine researcher, has received support from the Nouvelle-Aquitaine region and BPI France.The company has launched a fundraising effort to secure 4 million euros to finance the next stages of progress.
Remote-Controlled Chemotherapy: A Promising New Approach to Cancer Treatment
This article explores a cutting-edge approach to chemotherapy being developed by Doxanano, a biotech startup located near Bordeaux, France. The innovative method aims to revolutionize cancer treatment by remotely controlling chemotherapy, potentially improving effectiveness and minimizing side effects.
What is the current standard of care for chemotherapy?
The current standard of care in chemotherapy benefits approximately 60% of cancer patients. However, this often comes at a cost; a meaningful impact on their quality of life.
What are the limitations of traditional chemotherapy?
Traditional chemotherapy faces a significant challenge: balancing effectiveness and harm. As explained by Isabel Marey-Semper, co-founder of Doxanano, “the paradox of chemotherapy is a dose locally present in the tumor too weak to be completely effective and a dose too strong in the healthy organs to be harmless.” Currently,treatment is adjusted based on the patient’s tolerance.
How does remote-controlled chemotherapy work?
The new approach, developed by Doxanano, aims to refine chemotherapy based on the following:
Targeted Drug Delivery: The treatment uses specially designed nanocarriers called DXN.
Nanocarriers as “Safes”: thes nanocarriers are made of macromolecules that remain stable until activated by X-ray radiation.
Radiotherapy as a Trigger: The nanocarriers release the chemotherapy drugs directly into the tumor when exposed to radiotherapy.
Who is behind this new technology?
The key figures behind this innovative approach are:
Isabel Marey-Semper: Neuropharmacology doctor and co-founder of Doxanano.
Sébastien Lecommandoux: Physiochemist and co-founder of Doxanano. He is also the chair of “technological innovation Liliane Bettencourt”
dr. Charles Dupin: Cancerologist and radiotherapist who collaborated with doxanano.
Leslie Dubrana: Chemical engineer and nanomedicine researcher.
What are the potential benefits of this new treatment?
The goal is to improve patient survival rates and their quality of life by:
Delivering unprecedented doses of chemotherapy directly to the tumor.
safeguarding healthy organs.
Making the treatment more precise and less harmful.
What types of cancer might this treatment be used for?
Remote-controlled chemotherapy has the potential to be applied to all solid tumors. The initial focus is on advanced rectal tumors.
When will human trials begin?
Doxanano anticipates beginning its first human trials by the end of 2028, pending the completion of preclinical and clinical testing, and regulatory approvals.
Where is Doxanano located?
While Doxanano’s headquarters are in Paris, its research activities and future manufacturing plant are planned for Pessac, near Bordeaux, France.
What support has Doxanano received?
doxanano has received support from:
The Nouvelle-Aquitaine region
BPI France
How is Doxanano funding its research?
The company has launched a fundraising effort to secure 4 million euros to finance the next stages of progress.
Summary of Remote-Controlled Chemotherapy vs. Traditional Chemotherapy
| Feature | Remote-Controlled Chemotherapy (Doxanano) | Traditional Chemotherapy |
| ————————— | —————————————————————————————————————– | —————————————————————————————————————————– |
| Drug Delivery | Targeted, using nanocarriers activated by radiotherapy | Systemic, affecting both cancerous and healthy cells |
| Precision | High, due to targeted release within the tumor | lower, as dosage is limited by the patient’s tolerance |
| Side Effects | Potentially minimized due to targeted drug release | Frequently enough significant, due to the impact on healthy organs |
| Mechanism | Nanocarriers (DXN) release drugs upon exposure to X-ray radiation. | Drugs administered intravenously or orally. |
| Goal | Maximize effectiveness, minimize harm to healthy tissues, and improve patient quality of life and survival rates. | treat cancer, but often at a cost to the patient’s quality of life; treatment is adjusted based on the patient’s tolerance. |
| Current Stage | Initial animal studies are very promising; human trials anticipated by the end of 2028. | Standard of care for many cancer types. |
| Key Innovators | Isabel Marey-Semper, Sébastien Lecommandoux, Dr. Charles Dupin, and Leslie Dubrana | Various medical professionals |
| Location of Research| Pessac, France (near Bordeaux) | Varies |